Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Drugs
Published in: Drugs 9/2005

01-06-2005 | Review Article

Herb-Drug Interactions

A Literature Review

Authors: Zeping Hu, Xiaoxia Yang, Paul Chi Lui Ho, Sui Yung Chan, Paul Wan Sia Heng, Eli Chan, Wei Duan, Hwee Ling Koh, Dr Shufeng Zhou

Published in: Drugs | Issue 9/2005

Login to get access

Abstract

Herbs are often administered in combination with therapeutic drugs, raising the potential of herb-drug interactions. An extensive review of the literature identified reported herb-drug interactions with clinical significance, many of which are from case reports and limited clinical observations.
Cases have been published reporting enhanced anticoagulation and bleeding when patients on long-term warfarin therapy also took Salvia miltiorrhiza (danshen). Allium sativum (garlic) decreased the area under the plasma concentration-time curve (AUC) and maximum plasma concentration of saquinavir, but not ritonavir and paracetamol (acetaminophen), in volunteers. A. sativum increased the clotting time and international normalised ratio of warfarin and caused hypoglycaemia when taken with chlorpropamide. Ginkgo biloba (ginkgo) caused bleeding when combined with warfarin or aspirin (acetylsalicylic acid), raised blood pressure when combined with a thiazide diuretic and even caused coma when combined with trazodone in patients. Panax ginseng (ginseng) reduced the blood concentrations of alcohol (ethanol) and warfarin, and induced mania when used concomitantly with phenelzine, but ginseng increased the efficacy of influenza vaccination. Scutellaria baicalensis (huangqin) ameliorated irinotecan-induced gastrointestinal toxicity in cancer patients.
Piper methysticum (kava) increased the ‘off’ periods in patients with parkinsonism taking levodopa and induced a semicomatose state when given concomitantly with alprazolam. Kava enhanced the hypnotic effect of alcohol in mice, but this was not observed in humans. Silybum marianum (milk thistle) decreased the trough concentrations of indinavir in humans. Piperine from black (Piper nigrum Linn) and long (P. longum Linn) peppers increased the AUC of phenytoin, propranolol and theophylline in healthy volunteers and plasma concentrations of rifamipicin (rifampin) in patients with pulmonary tuberculosis. Eleutheroccus senticosus (Siberian ginseng) increased the serum concentration of digoxin, but did not alter the pharmacokinetics of dextromethorphan and alprazolam in humans. Hypericum perforatum (hypericum; St John’s wort) decreased the blood concentrations of ciclosporin (cyclosporin), midazolam, tacrolimus, amitriptyline, digoxin, indinavir, warfarin, phenprocoumon and theophylline, but did not alter the pharmacokinetics of carbamazepine, pravastatin, mycophenolate mofetil and dextromethorphan. Cases have been reported where decreased ciclosporin concentrations led to organ rejection. Hypericum also caused breakthrough bleeding and unplanned pregnancies when used concomitantly with oral contraceptives. It also caused serotonin syndrome when used in combination with selective serotonin reuptake inhibitors (e.g. sertraline and paroxetine).
In conclusion, interactions between herbal medicines and prescribed drugs can occur and may lead to serious clinical consequences. There are other theoretical interactions indicated by preclinical data. Both pharmacokinetic and/or pharmacodynamic mechanisms have been considered to play a role in these interactions, although the underlying mechanisms for the altered drug effects and/or concentrations by concomitant herbal medicines are yet to be determined. The clinical importance of herb-drug interactions depends on many factors associated with the particular herb, drug and patient. Herbs should be appropriately labeled to alert consumers to potential interactions when concomitantly used with drugs, and to recommend a consultation with their general practitioners and other medical carers.
Literature
1.
Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: a systematic review. Drugs 2001; 61(15): 2163–75PubMedCrossRef
2.
Fugh-Berman A. Herbal medicinals: selected clinical considerations, focusing on known or potential drug-herb interactions. Arch Intern Med 1999; 159(16): 1957–8PubMedCrossRef
3.
4.
Fugh-Berman A, Ernst E. Herb-drug interactions: review and assessment of report reliability. Br J Clin Pharmacol 2001; 52(5): 587–95PubMedCrossRef
5.
Heck AM, DeWitt BA, Lukes AL. Potential interactions between alternative therapies and warfarin. Am J Health System Pharm 2000; 57(13): 1221–7
6.
Elvin-Lewis M. Should we be concerned about herbal remedies. J Ethnopharmacol 2001; 75(2–3): 141–64PubMedCrossRef
7.
Wilkinson GR. The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. Adv Drug Deliv Rev 1997; 27(2–3): 129–59PubMedCrossRef
8.
Evans AM. Influence of dietary components on the gastrointestinal metabolism and transport of drugs. Ther Drug Monit 2000; 22(1): 131–6PubMedCrossRef
9.
Ioannides C. Pharmacokinetic interactions between herbal remedies and medicinal drugs. Xenobiotica 2002; 32(6): 451–78PubMedCrossRef
10.
Zhou SF, Gao YH, Wen QJ, et al. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 35(1): 35–98PubMedCrossRef
11.
Walter-Sack I, Klotz U. Influence of diet and nutritional status on drug metabolism. Clin Pharmacokinet 1996; 31: 47–64PubMedCrossRef
12.
Kolars JC, Awni WM, Merion RM, et al. First-pass metabolism of cyclosporin by the gut. Lancet 1991; 338: 1488–90PubMedCrossRef
13.
Paine MF, Shen DD, Kunze KL, et al. First-pass metabolism of midazolam by the human intestine. Clin Pharmacol Ther 1996; 60: 14–24PubMedCrossRef
14.
Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 1998; 101(2): 289–94PubMedCrossRef
15.
Fromm MF, Busse D, Kroemer HK, et al. Differential induction of prehepatic and hepatic metabolism of verapamil by rifampin. Hepatology 1996; 24: 796–801PubMedCrossRef
16.
Greiner B, Eichelbaum M, Fritz P, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147–53PubMedCrossRef
17.
Westphal K, Weinbrenner A, Zschiesche M, et al. Induction of P-glycoprotein by rifampin increases intestinal secretion of talinolol in human beings: a new type of drug/drug interaction. Clin Pharmacol Ther 2000; 68: 345–55PubMedCrossRef
18.
Eisenberg DM, Kessler RC, Foster C, et al. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 1993; 328: 246–52PubMedCrossRef
19.
Goldman P. Herbal medicines today and the roots of modern pharmacology. Ann Intern Med 2001; 135 (8 Pt 1): 594–600PubMed
20.
Shaw D, Leon C, Kolev S, et al. Traditional remedies and food supplements: a 5-year toxicological study (1991–1995). Drug Saf 1997; 17(5): 342–56PubMedCrossRef
21.
WHO. WHO monographs on selected medicinal plants. Vol. 2. Geneva: World Health Organization, 2002
22.
WHO. WHO monographs on selected medicinal plants. Vol. 1. Geneva: World Health Organization, 1999
23.
Hoffmann D. The information sourcebook of herbal medicine. Freedom (CA): Crossing Press, 1994
24.
Ernst E. Herbal medicine: a concise overview for professionals. Boston (MA): Butterworth-Heinemann, 1999
25.
Ross IA. Medicinal plants of the world: chemical constituents, traditional, and modern medicinal uses. Totowa (NJ): Humana Press, 2001
26.
Fetrow CW, Avila JR. The complete guide to herbal medicines. Springhouse (PA): Springhouse Corp., 2000
27.
Huang KC. The pharmacology of Chinese herbs. Boca Raton (FL): CRC Press, 1998CrossRef
28.
Yang YF. Chinese herbal medicines: comparisons and characteristics. Edinburgh: Churchill Livingstone, 2002
29.
Izzo AA, Borrelli F, Capasso R. Herbal medicine: the dangers of drug interaction. Trends Pharmacol Sci 2002; 23(8): 358–91PubMedCrossRef
30.
Scott GN, Elmer GW. Update on natural product-drug interactions. Am J Health Syst Pharm 2002; 59(4): 339–47PubMed
31.
Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm 1999; 56(2): 125–38PubMed
32.
Abebe W. Herbal medication: potential for adverse interactions with analgesic drugs. J Clin Pharm Ther 2002; 27(6): 391–401PubMedCrossRef
33.
Brazier NC, Levine MA. Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther 2003; 10(3): 163–9PubMedCrossRef
34.
Zhou S, Chan E, Pan SQ, et al. Pharmacokinetic interactions of drugs with St John’s wort. J Psychopharmacol 2004; 18(2): 262–76PubMedCrossRef
35.
Izzo AA, Di Carlo G, Borrelli F, et al. Cardiovascular pharmacotherapy and herbal medicines: the risk of drug interaction. Int J Cardiol 2005; 98(1): 1–14PubMedCrossRef
36.
Sparreboom A, Cox MC, Acharya MR, et al. Herbal remedies in the United States: potential adverse interactions with anti-cancer agents. J Clin Oncol 2004; 22(12): 2489–503PubMedCrossRef
37.
Izzo AA. Herb-drug interactions: an overview of the clinical evidence. Fundam Clin Pharmacol 2005; 19(1): 1–16PubMedCrossRef
38.
Harris JC, Cottrell SL, Plummer S, et al. Antimicrobial properties of Allium sativum (garlic). Appl Microbiol Biotechnol 2001; 57(3): 282–6PubMedCrossRef
39.
Kyo E, Uda N, Kasuga S, et al. Immunomodulatory effects of aged garlic extract. J Nutr 2001; 131(3s): S1075–9
40.
Standish LJ, Greene KB, Bain S, et al. Alternative medicine use in HIV-positive men and women: demographics, utilization patterns and health status. AIDS Care 2001; 13(2): 197–208PubMedCrossRef
41.
Dausch JG, Nixon DW. Garlic: a review of its relationship to malignant disease. Prev Med 1990; 19(3): 346–61PubMedCrossRef
42.
Singh UP, Prithiviraj B, Sarma BK, et al. Role of garlic (Allium sativum L.) in human and plant diseases. Indian J Exp Biol 2001; 39(4): 310–22PubMed
43.
Amagase H, Petesch BL, Matsuura H, et al. Intake of garlic and its bioactive components. J Nutr 2001; 131 Suppl. 3: 955S–62SPubMed
44.
Markowitz JS, Devane CL, Chavin KD, et al. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther 2003; 74(2): 170–7PubMedCrossRef
45.
Gurley BJ, Gardner SF, Hubbard MA, et al. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther 2002; 72(3): 276–87PubMedCrossRef
46.
Fitzsimmons ME, Collins JM. Selective biotransformation of the human immunodeficiency virus protease inhibitor saquinavir by human small-intestinal cytochrome P450 3A4: potential contribution to high first-pass metabolism. Drug Metab Dispos 1997; 25(2): 256–66PubMed
47.
Foster BC, Foster MS, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharm Sci 2001; 4(2): 176–84PubMed
48.
Piscitelli SC, Burstein AH, Weiden N, et al. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis 2002; 34(2): 234–8PubMedCrossRef
49.
Kim AE, Dintaman JM, Waddell DS. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 1998; 286: 143–9
50.
Gisolf EH, van Heeswijk RP, Hoetelmans RW, et al. Decreased exposure to saquinavir in HIV-1infected patients after long-term antiretroviral therapy including ritonavir and saquinavir. AIDS 2000; 14: 801–5PubMedCrossRef
51.
Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol 2003; 55(2): 199–202PubMedCrossRef
52.
Hsu A, Granneman GR, Bertz RJ. Ritonavir: clinical pharmacokinetics and interactions with other anti-HIV agents. Clin Pharmacokinet 1998; 35(4): 275–91PubMedCrossRef
53.
Laroche M, Choudhri S, Gallicano K, et al. Severe gastrointestinal toxicity with concomitant ingestion of ritonavir and garlic [abstract]. Can J Infect Dis 1998; 9 Suppl. A: 471P
54.
Ernst E. Complementary AIDS therapies: the good, the bad, and the ugly. Int J STD AIDS 1997; 8(5): 281–5PubMedCrossRef
55.
Sussman E. Garlic supplements can impede HIV medication [letter]. AIDS 2002; 16(9): N5CrossRef
56.
Sunter WH. Warfarin and garlic [letter]. Pharm J 1991; 246: 772
57.
Evans V. Herbs and the brain: friend or foe? The effects of ginkgo and garlic on warfarin use. J Neurosci Nurs 2000; 32(4): 229–32PubMedCrossRef
58.
59.
60.
Rose KD, Croissant PD, Parliament CF, et al. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery 1990; 26(5): 880–2PubMedCrossRef
61.
62.
Briggs WH, Xiao H, Parkin KL, et al. Differential inhibition of human platelet aggregation by selected Allium thiosulfinates. J Agric Food Chem 2000; 48(11): 5731–5PubMedCrossRef
63.
Rahman K, Billington D. Dietary supplementation with aged garlic extract inhibits ADP-induced platelet aggregation in humans. J Nutr 2000; 130(11): 2662–5PubMed
64.
MacDonald JA, Langler RF. Structure-activity relationships for selected sulfur-rich antithrombotic compounds. Biochem Biophys Res Commun 2000; 273(2): 421–4PubMedCrossRef
65.
Bordia A, Verma SK, Srivastava KC. Effect of garlic (Allium sativum) on blood lipids, blood sugar, fibrinogen and fibrinolytic activity in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 1998; 58(4): 257–63PubMedCrossRef
66.
Aslam M, Stockley IH. Interaction between curry ingredient (karela) and drug (chlorpropamide) [letter]. Lancet 1979; I(8116): 607CrossRef
67.
Sheela CG, Kumud K, Augusti KT. Anti-diabetic effects of onion and garlic sulfoxide amino acids in rats. Planta Med 1995; 61(4): 356–7PubMedCrossRef
68.
Sheela CG, Augusti KT. Antidiabetic effects of S-allyl cysteine sulphoxide isolated from garlic Allium sativum Linn. Indian J Exp Biol 1992; 30(6): 523–6PubMed
69.
Mathew PT, Augusti KT. Studies on the effect of allicin (diallyl disulphide-oxide) on alloxan diabetes. I: hypoglycaemic action and enhancement of serum insulin effect and glycogen synthesis. Indian J Biochem Biophys 1973; 10(3): 209–12PubMed
70.
Zhang XH, Lowe D, Giles P, et al. Gender may affect the action of garlic oil on plasma cholesterol and glucose levels of normal subjects. J Nutr 2001; 131(5): 1471–8PubMed
71.
Sitprija S, Plengvidhya C, Kangkaya V, et al. Garlic and diabetes mellitus phase II clinical trial. J Med Assoc Thai 1987; 70 Suppl. 2: 223–7PubMed
72.
Day C, Cartwright T, Provost J, et al. Hypoglycaemic effect of Momordica charantia extracts. Planta Med 1990; 56(5): 426–9PubMedCrossRef
73.
Gwilt PR, Lear CL, Tempero MA, et al. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev 1994; 3(2): 155–60PubMed
74.
Lin MC, Wang EJ, Patten C, et al. Protective effect of diallyl sulfone against acetaminophen-induced hepatotoxicity in mice. J Biochem Toxicol 1996; 11(1): 11–20PubMedCrossRef
75.
Manyike PT, Kharasch ED, Kalhorn TF, et al. Contribution of CYP2E1 and CYP3A to acetaminophen reactive metabolite formation. Clin Pharmacol Ther 2000; 67(3): 275–82PubMedCrossRef
76.
Li H, Dai Y, Zhang H, et al. Pharmacological studies on the Chinese drug radix Angelicae dahuricae. Zhongguo Zhong Yao Za Zhi 1991; 16(9): 560–76PubMed
77.
Kim CM, Heo MY, Kim HP, et al. Pharmacological activities of water extracts of Umbelliferae plants. Arch Pharm Res 1991; 14(1): 87–92PubMedCrossRef
78.
Saiki Y, Morinaga K, Okegawa O, et al. On the coumarins of the roots of Angelica dahurica Benth. et Hook. Yakugaku Zasshi 1971; 91(12): 1313–7PubMed
79.
Baek NI, Ahn EM, Kim HY, et al. Furanocoumarins from the root of Angelica dahurica. Arch Pharm Res 2000; 23(5): 467–70PubMedCrossRef
80.
Qiao SY, Yao XS, Wang ZY. Coumarins of the roots of Angelica dahurica [abstract]. Planta Med 1996; 62(6): 584PubMedCrossRef
81.
Ishihara K, Kushida H, Yuzurihara M, et al. Interaction of drugs and Chinese herbs: pharmacokinetic changes of tolbutamide and diazepam caused by extract of Angelica dahurica. J Pharm Pharmacol 2000; 52(8): 1023–9PubMedCrossRef
82.
Bergendorff O, Dekermendjian K, Nielsen M, et al. Furanocoumarins with affinity to brain benzodiazepine receptors in vitro. Phytochemistry 1997; 44(6): 1121–11124PubMedCrossRef
83.
Dekermendjian K, Ai JL, Nielsen M, et al. Characterisation of the furanocoumarin phellopterin as a rat brain benzodiazepine receptor partial agonist in vitro. Neurosci Lett 1996; 219(3): 151–4PubMedCrossRef
84.
Cai Y, Bennett D, Nair RV, et al. Inhibition and inactivation of murine hepatic ethoxy- and pentoxyresorufin O-dealkylase by naturally occurring coumarins. Chem Res Toxicol 1993; 6(6): 872–9PubMedCrossRef
85.
Kleiner HE, Vulimiri SV, Reed MJ, et al. Role of cytochrome P450 1A1 and 1B1 in the metabolic activation of 7,12-dimethylbenz[a]anthracene and the effects of naturally occurring furanocoumarins on skin tumor initiation. Chem Res Toxicol 2002; 15(2): 226–35PubMedCrossRef
86.
Kleiner HE, Reed MJ, DiGiovanni J. Naturally occurring coumarins inhibit human cytochromes P450 and block benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene DNA adduct formation in MCF-7 cells. Chem Res Toxicol 2003; 16(3): 415–22PubMedCrossRef
87.
Maenpaa J, Sigusch H, Raunio H, et al. Differential inhibition of coumarin 7-hydroxylase activity in mouse and human liver microsomes. Biochem Pharmacol 1993; 45(5): 1035–42PubMedCrossRef
88.
Guo LQ, Taniguchi M, Chen QY, et al. Inhibitory potential of herbal medicines on human cytochrome P450-mediated oxidation: properties of Umbelliferous or Citrus crude drugs and their relative prescriptions. Jpn J Pharmacol 2001; 85(4): 399–408PubMedCrossRef
89.
90.
Lin LZ, He XG, Lian LZ, et al. Liquid Chromatographic electrospray mass spectrometric study of the phthalides of Angelica sinensis and chemical changes of Z-ligustilide. J Chromatogr 1998; 810(1–2): 71–9
91.
Zhao KJ, Dong TT, Tu PF, et al. Molecular genetic and chemical assessment of Radix Angelica (Danggui) in China. J Agric Food Chem 2003; 51(9): 2576–83PubMedCrossRef
92.
Huang WH, Song CQ. Research progresses in the chemistry and pharmacology of Angelica sinensis (Oliv.) Diel [in Chinese]. Zhongguo Zhong Yao Za Zhi 2001; 26(3): 147–51PubMed
93.
Mao X, Kong L, Luo Q, et al. Screening and analysis of permeable compounds in Radix Angelica Sinensis with immobilized liposome chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 779(2): 331–9PubMedCrossRef
94.
Ji SG, Chai YF, Wu YT, et al. Determination of ferulic acid in Angelica sinensis and Chuanxiong by capillary zone electrophoresis. Biomed Chromatogr 1999; 13(5): 333–4PubMedCrossRef
95.
Guo T, Sun Y, Sui Y, et al. Determination of ferulic acid and adenosine in Angelicae Radix by micellar electrokinetic chromatography. Anal Bioanal Chem 2003; 375(6): 840–3PubMed
96.
Yang Q, Populo SM, Zhang J, et al. Effect of Angelica sinensis on the proliferation of human bone cells. Clin Chim Acta 2002; 324(1–2): 89–97PubMedCrossRef
97.
Mei QB, Tao JY, Cui B. Advances in the pharmacological studies of radix Angelica sinensis (Oliv) Diels (Chinese Danggui). Chin Med J (Engl) 1991; 104(9): 776–81
98.
Russell L, Hicks GS, Low AK, et al. Phytoestrogens: a viable option? Am J Med Sci 2002; 324(4): 185–8PubMedCrossRef
99.
He ZP, Wang DZ, Shi LY, et al. Treating amenorrhea in vital energy-deficient patients with angelica sinensis-astragalus membranaceus menstruation-regulating decoction. J Tradit Chin Med 1986; 6(3): 187–90PubMed
100.
Hardy ML. Herbs of special interest to women. J Am Pharm Assoc (Wash) 2000; 40(2): 234–42
101.
Hirata JD, Swiersz LM, Zeil B, et al. Does dong quai have estrogenic effects in postmenopausal women? A double-blind, placebo-controlled trial. Fertil Steril 1997; 68(6): 981–6PubMedCrossRef
102.
Page 2nd RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy 1999; 19(7): 870–6PubMedCrossRef
103.
Yin ZZ, Zhang LY, Xu LN. The effect of Dang-Gui (Angelica sinensis) and its ingredient ferulic acid on rat platelet aggregation and release of 5-HT (author’s transi) [in Chinese]. Yao Xue Xue Bao 1980; 15(6): 321–6PubMed
104.
Lo ACT, Chan K, Yeung JHK, et al. Danggui (Angelica sinensis) affects the pharmacodynamics but not the pharmacokinetics of warfarin in rabbits. Eur J Drug Metab Pharmacokinet 1995; 20(1): 55–60PubMedCrossRef
105.
Teel RW, Huynh H. Modulation by phytochemicals of cytochrome P450-linked enzyme activity. Cancer Lett 1998; 133(2): 135–41PubMedCrossRef
106.
Li T. Siberian ginseng. Horttechnology 2001; 11: 79–84
107.
Gaffney B, Hugel H, Rich P. The effects of Eleutherococcus senticosus and Panax ginseng on steroidal hormone indices of stress and lymphocyte subset numbers in endurance athletes. Life Sci 2001; 70(4): 431–42PubMedCrossRef
108.
Davydov M, Krikorian AD. Eleutherococcus senticosus (Rupr. & Maxim.) Maxim. (Araliaceae) as an adaptogen: a closer look. J Ethnopharmacol 2000; 72(3): 345–93PubMedCrossRef
109.
Hou JP. The chemical constituents of ginseng plants. Comp Med East West 1977; 5(2): 123–45PubMed
110.
Donovan JL, DeVane CL, Chavin KD, et al. Siberian ginseng (Eleutheroccus senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos 2003; 31(5): 519–22PubMedCrossRef
111.
Budzinski JW, Foster BC, Vandenhoek S, et al. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7(4): 273–82PubMedCrossRef
112.
Medon PJ, Ferguson PW, Watson CF. Effects of Eleuthewcoccus senticosus extracts on hexobarbital metabolism in vivo and in vitro. J Ethnopharmacol 1984; 10(2): 235–41PubMedCrossRef
113.
Knodell RG, Dubey RK, Wilkinson GR, et al. Oxidative metabolism of hexobarbital in human liver: relationship to polymorphic S-mephenytoin 4-hydroxylation. J Pharmacol Exp Ther 1988; 245(3): 845–9PubMed
114.
McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. CMAJ 1996; 155(3): 293–5PubMed
115.
Dasgupta A, Wu S, Actor J, et al. Effect of Asian and Siberian ginseng on serum digoxin measurement by five digoxin immunoassays: significant variation in digoxin-like immunoreactivity among commercial ginsengs. Am J Clin Pathol 2003; 119(2): 298–303PubMedCrossRef
116.
Oken BS, Storzbach DM, Kaye JA. The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 1998; 55(11): 1409–15PubMedCrossRef
117.
McKenna DJ, Jones K, Hughes K. Efficacy, safety, and use of ginkgo biloba in clinical and preclinical applications. Altern Ther Health Med 2001; 7(5): 70–86PubMed
118.
Wesnes KA, Ward T, McGinty A, et al. The memory enhancing effects of a Ginkgo biloba/Panax ginseng combination in healthy middle-aged volunteers. Psychopharmacology 2000: 152(4): 353–61PubMedCrossRef
119.
Mahady GB. Ginkgo biloba for the prevention and treatment of cardiovascular disease: a review of the literature}. J Cardiovasc Nurs 2002; 16(4): 21–32PubMed
120.
Diamond BJ, Shiflett SC, Feiwel N, et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil 2000; 81(5): 668–78PubMed
121.
Andrieu S, Gillette S, Amouyal K, et al. Association of Alzheimer’s disease onset with ginkgo biloba and other symptomatic cognitive treatments in a population of women aged 75 years and older from the EPIDOS study. J Gerontol A Biol Sci Med Sci 2003; 58(4): 372–7PubMedCrossRef
122.
Ponto LL, Schultz SK. Ginkgo biloba extract: review of CNS effects. Ann Clin Psychiatry 2003; 15(2): 109–19PubMed
123.
Tang YP, Lou FC, Wang JH, et al. Coumaroyl flavonol glycosides from the leaves of Ginkgo biloba. Phytochemistry 2001; 58(8): 1251–6PubMedCrossRef
124.
Krieglstein J, Ausmeier F, Elabhar H, et al. Neuroprotective effects of Ginkgo biloba constituents. Eur J Pharm Sci 1995; 3(1): 39–48CrossRef
125.
van Beek TA. Chemical analysis of Ginkgo biloba leaves and extracts. J Chromatogr A 2002; 967(1): 21–55PubMedCrossRef
126.
Lichtblau D, Berger JM, Nakanishi K. Efficient extraction of ginkgolides and bilobalide from Ginkgo biloba leaves. J Nat Prod 2002; 65(10): 1501–4PubMedCrossRef
127.
Jaggy H, Koch E. Chemistry and biology of alkylphenols from Ginkgo biloba L. Pharmazie 1997; 52(10): 735–8PubMed
128.
Baron-Ruppert G, Luepke NP. Evidence for toxic effects of alkylphenols from Ginkgo biloba in the hen’s egg test (HET). Phytomedicine 2001; 8(2): 133–8PubMedCrossRef
129.
Ahlemeyer B, Selke D, Schaper C, et al. Ginkgolic acids induce neuronal death and activate protein phosphatase type-2C. Eur J Pharmacol 2001; 430(1): 1–7PubMedCrossRef
130.
Koch E, Jaggy H, Chatterjee SS. Evidence for immunotoxic effects of crude Ginkgo biloba L. leaf extracts using the popliteal lymph node assay in the mouse. Int J Immunopharmacol 2000; 22(3): 229–36PubMedCrossRef
131.
Lepoittevin JP, Benezra C, Asakawa Y. Allergic contact dermatitis to Ginkgo biloba L.: relationship with urushiol. Arch Dermatol Res 1989; 281(4): 227–30PubMedCrossRef
132.
Galluzzi S, Zanetti O, Binetti G, et al. Coma in a patient with Alzheimer’s disease taking low dose trazodone and Ginkgo biloba. J Neurol Neurosurg Psychiatry 2000; 68(5): 679–80PubMedCrossRef
133.
Sasaki K, Hatta S, Haga M, et al. Effects of bilobalide on gamma-aminobutyric acid levels and glutamic acid decarboxylase in mouse brain. Eur J Pharmacol 1999; 367 (2–3): 165–73
134.
Sasaki K, Hatta S, Wada K, et al. Bilobalide prevents reduction of gamma-aminobutyric acid levels and glutamic acid decarboxylase activity induced by 4-O-methylpyridoxine in mouse hippocampus. Life Sci 2000; 67(6): 709–15PubMedCrossRef
135.
Shinozuka K, Umegaki K, Kubota Y, et al. Feeding of Ginkgo biloba extract (GBE) enhances gene expression of hepatic cytochrome P-450 and attenuates the hypotensive effect of nicardipine in rats. Life Sci 2002; 70(23): 2783–92PubMedCrossRef
136.
Umegaki K, Saito K, Kubota Y, et al. Ginkgo biloba extract markedly induces pentoxyresorufin O-dealkylase activity in rats. Jpn J Pharmacol 2002; 90(4): 345–51PubMedCrossRef
137.
Sasaki K, Wada K, Hatta S, et al. Bilobalide, a constituent of Ginkgo biloba L., potentiates drug-metabolizing enzyme activities in mice: possible mechanism for anticonvulsant activity against 4-O-methylpyridoxine-induced convulsions. Res Commun Mol Pathol Pharmacol 1997; 96(1): 45–56PubMed
138.
Vaes LP, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother 2000; 34(12): 1478–82PubMedCrossRef
139.
Matthews Jr MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology 1998; 50(6): 1933–4PubMedCrossRef
140.
Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract [letter]. N Engl J Med 1997: 336(15): 1108PubMedCrossRef
141.
Meisel C, Johne A, Roots I. Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen. Atherosclerosis 2003; 167(2): 367PubMedCrossRef
142.
Engelsen J, Nielsen JD, Hansen KF. Effect of coenzyme Q10 and Ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment: a randomized, double-blind, placebo-controlled cross-over trial [in Danish]. Ugeskr Laeger 2003; 165(18): 1868–71PubMed
143.
Kim YS, Pyo MK, Park KM, et al. Antiplatelet and antithrombotic effects of a combination of ticlopidine and Ginkgo biloba ext (EGb 761). Thromb Res 1998; 91(1): 33–8PubMedCrossRef
144.
Lamant V, Mauco G, Braquet P, et al. Inhibition of the metabolism of platelet activating factor (PAF-acether) by three specific antagonists from Ginkgo biloba. Biochem Pharmacol 1987; 36(17): 2749–52PubMedCrossRef
145.
Fessenden JM, Wittenborn W, Clarke L. Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg 2001; 67(1): 33–5PubMed
146.
147.
Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba [letter]. Lancet 1998; 352(9121): 36PubMedCrossRef
148.
Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology 1996; 46(6): 1775–6PubMedCrossRef
149.
Bal Dit Sollier C, Caplain H, Drouet L. No alteration in platelet function or coagulation induced by EGb761 in a controlled study. Clin Lab Haematol 2003; 25(4): 251–3PubMedCrossRef
150.
Mauro VF, Mauro LS, Kleshinski JF, et al. Impact of ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther 2003; 10(4): 247–51PubMedCrossRef
151.
Yin OQ, Tomlinson B, Waye MM, et al. Pharmacogenetics and herb-drug interactions: experience with Ginkgo biloba and omeprazole. Pharmacogenetics 2004; 14(12): 841–50PubMedCrossRef
152.
Ohnishi N, Kusuhara M, Yoshioka M, et al. Studies on interactions between functional foods or dietary supplements and medicines. I: effects of Ginkgo biloba leaf extract on the pharmacokinetics of diltiazem in rats. Biol Pharm Bull 2003; 26(9): 1315–20PubMedCrossRef
153.
Kalus JS, Piotrowski AA, Fortier CR, et al. Hemodynamic and electrocardiographic effects of short-term ginkgo biloba. Ann Pharmacother 2003; 37(3): 345–9PubMedCrossRef
154.
Mehlsen J, Drabaek H, Wiinberg N, et al. Effects of a Ginkgo biloba extract on forearm haemodynamics in healthy volunteers. Clin Physiol Funct Imaging 2002; 22(6): 375–8PubMedCrossRef
155.
Jezova D, Duncko R, Lassanova M, et al. Reduction of rise in blood pressure and cortisol release during stress by Ginkgo biloba extract (EGb 761) in healthy volunteers. J Physiol Pharmacol 2002; 53(3): 337–48PubMed
156.
Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract on pancreatic beta-cell function in response to glucose loading in normal glucose tolerant individuals. J Clin Pharmacol 2000; 40(6): 647–54PubMedCrossRef
157.
Zhang J, Fu S, Liu S, et al. The therapeutic effect of Ginkgo biloba extract in SHR rats and its possible mechanisms based on cerebral microvascular flow and vasomotion. Clin Hemorheol Microcirc 2000; 23(2–4): 133–8PubMed
158.
Umegaki K, Shinozuka K, Watarai K, et al. Ginkgo biloba extract attenuates the development of hypertension in deoxycorticosterone acetate-salt hypertensive rats. Clin Exp Pharmacol Physiol 2000; 27(4): 277–82PubMedCrossRef
159.
Chermat R, Brochet D, DeFeudis FV, et al. Interactions of Ginkgo biloba extract (EGb 761), diazepam and ethyl betacarboline-3-carboxylate on social behavior of the rat. Pharmacol Biochem Behav 1997; 56(2): 333–9PubMedCrossRef
160.
Nordberg A, Svensson AL. Cholinesterase inhibitors in the treatment of Alzheimer’s disease: a comparison of tolerability and pharmacology. Drug Saf 1998; 19(6): 465–80PubMedCrossRef
161.
Yasui-Furukori N, Furukori H, Kaneda A, et al. The effects of Ginkgo biloba extracts on the pharmacokinetics and pharmacodynamics of donepezil. J Clin Pharmacol 2004; 44(5): 538–42PubMedCrossRef
162.
Jann MW, Shirley KL, Small GW. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002; 41(10): 719–39PubMedCrossRef
163.
Wada K, Ishigaki S, Ueda K, et al. Studies on the constitution of edible and medicinal plants. I: isolation and identification of 4-O-methylpyridoxine, toxic principle from the seed of Ginkgo biloba L. Chem Pharm Bull (Tokyo) 1988; 36(5): 1779–82
164.
Scott PM, Lau BP, Lawrence GA, et al. Analysis of Ginkgo biloba for the presence of ginkgotoxin and ginkgotoxin 5’-glucoside. J AOAC Int 2000; 83(6): 1313–20PubMed
165.
Zhang XY, Zhou DF, Su JM, et al. The effect of extract of Ginkgo biloba added to haloperidol on Superoxide dismutase in inpatients with chronic schizophrenia. J Clin Psychopharmacol 2001; 21(1): 85–8PubMedCrossRef
166.
Zhang XY, Zhou DF, Zhang PY, et al. A double-blind, placebocontrolled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia. J Clin Psychiatry 2001; 62(11): 878–83PubMedCrossRef
167.
Kudolo GB. The effect of 3-month ingestion of Ginkgo biloba extract (EGb 761) on pancreatic beta-cell function in response to glucose loading in individuals with non-insulin-dependent diabetes mellitus. J Clin Pharmacol 2001; 41(6): 600–11PubMedCrossRef
168.
Sugiyama T, Kubota Y, Shinozuka K, et al. Ginkgo biloba extract modifies hypoglycemic action of tolbutamide via hepatic cytochrome P450 mediated mechanism in aged rats. Life Sci 2004; 75(9): 1113–22PubMedCrossRef
169.
Hatano T, Fukuda T, Miyase T, et al. Phenolic constituents of licorice. III: structures of glicoricone and licofuranone, and inhibitory effects of licorice constituents on monoamine oxidase. Chem Pharm Bull (Tokyo) 1991; 39(5): 1238–43
170.
Hatano T, Fukuda T, Liu YZ, et al. Phenolic constituents of licorice. IV: correlation of phenolic constituents and licorice specimens from various sources, and inhibitory effects of licorice extracts on xanthine oxidase and monoamine oxidase. Yakugaku Zasshi 1991; 111(6): 311–21
171.
Li C, Homma M, Oka K. Characteristics of delayed excretion of flavonoids in human urine after administration of Shosaiko-to, a herbal medicine. Biol Pharm Bull 1998; 21(12): 1251–7PubMedCrossRef
172.
Shon JH, Park JY, Kim MS, et al. Effect of licorice (Radix glycyrrhizae) on the pharmacokinetics and pharmacodynamics of midazolam in healthy subjects [abstract]. Clin Pharmacol Ther 2001; 69: P78
173.
Gorski JC, Hall SD, Jones DR, et al. Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem Pharmacol 1994; 47(9): 1643–53PubMedCrossRef
174.
Kent UM, Aviram M, Rosenblat M, et al. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450S 3A4, 2B6, and 2C9. Drug Metab Dispos 2002; 30(6): 709–15PubMedCrossRef
175.
Paolini M, Pozzetti L, Sapone A, et al. Effect of licorice and glycyrrhizin on murine liver CYP-dependent monooxygenases. Life Sci 1998; 62(6): 571–82PubMedCrossRef
176.
Homma M, Oka K, Ikeshima K, et al. Different effects of traditional Chinese medicines containing similar herbal constituents on prednisolone pharmacokinetics. J Pharm Pharmacol 1995; 47(8): 687–92PubMedCrossRef
177.
Akao T, Terasawa T, Hiai S, et al. Inhibitory effects of glycyrrhetic acid derivatives on 11 beta- and 3 alpha-hydroxysteroid dehydrogenases of rat liver. Chem Pharm Bull (Tokyo) 1992; 40(11): 3021–4CrossRef
178.
Ojima M, Satoh K, Gomibuchi T, et al. The inhibitory effects of glycyrrhizin and glycyrrhetinic acid on the metabolism of cortisol and prednisolone: in vivo and in vitro studies. Nippon Naibunpi Gakkai Zasshi 1990; 66(5): 584–96PubMed
179.
Davis EA, Morris DJ. Medicinal uses of licorice through the millennia: the good and plenty of it. Mol Cell Endocrinol 1991; 78(1–2): 1–6PubMedCrossRef
180.
Teelucksingh S, Mackie AD, Burt D, et al. Potentiation of hydrocortisone activity in skin by glycyrrhetinic acid. Lancet 1990; 335(8697): 1060–3PubMedCrossRef
181.
Souness GW, Morris DJ. The antinatriuretic and kaliuretic effects of the glucocorticoids corticosterone and cortisol following pretreatment with carbenoxolone sodium (a liquorice derivative) in the adrenalectomized rat. Endocrinology 1989; 124(3): 1588–90PubMedCrossRef
182.
Elinav E, Chajek-Shaul T. Licorice consumption causing severe hypokalemic paralysis. Mayo Clin Proc 2003; 78(6): 767–8PubMedCrossRef
183.
Lin SH, Yang SS, Chau T, et al. An unusual cause of hypokalemic paralysis: chronic licorice ingestion. Am J Med Sci 2003; 325(3): 153–6PubMedCrossRef
184.
Nishimura N, Naora K, Hirano H, et al. Effects of sho-saiko-to (xiao chai hu tang), a Chinese traditional medicine, on the gastric function and absorption of tolbutamide in rats. Yakugaku Zasshi 2001; 121(2): 153–9PubMedCrossRef
185.
Nishimura N, Naora K, Hirano H, et al. Effects of Sho-saiko-to on the pharmacokinetics and pharmacodynamics of tolbutamide in rats. J Pharm Pharmacol 1998; 50(2): 231–6PubMedCrossRef
186.
Bilia AR, Gallori S, Vincieri FF. St John’s wort and depression: efficacy, safety and tolerability: an update. Life Sci 2002; 70(26): 3077–96PubMedCrossRef
187.
Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St John’s wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294(1): 88–95PubMed
188.
Erdelmeier CAJ. Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L. Pharmacopsychiatry 1998; 31S: 2–6CrossRef
189.
Moore LB, Goodwin B, Jones SA, et al. St John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Natl Acad Sci U S A 2000; 97(13): 7500–2PubMedCrossRef
190.
Kerb R, Brockmoller J, Staffeldt B, et al. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996; 40(9): 2087–93PubMed
191.
Schulz HU, Schurer M, Bassler D, et al. Investigation of the bioavailability of hypericin, pseudohypericin, hyperforin and the flavonoids quercetin and isorhamnetin following single and multiple oral dosing of a hypericum extract containing tablet. Arzneimittelforschung 2005; 55(1): 15–22PubMed
192.
Johne A, Schmider J, Brockmoller J, et al. Decreased plasma levels of amitriptyline and its metabolites on comedication with an extract from St John’s wort (Hypericum perforatum). J Clin Psychopharmacol 2002; 22(1): 46–54PubMedCrossRef
193.
Venkatakrishnan K, Schmider J, Harmatz JS, et al. Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol 2001; 41(10): 1043–54PubMedCrossRef
194.
Venkatakrishnan K, Greenblatt DJ, von Moltke LL, et al. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol 1998; 38(2): 112–21PubMed
195.
Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Nortriptyline E-10-hydroxylation in vitro is mediated by human CYP2D6 (high affinity) and CYP3A4 (low affinity): implications for interactions with enzyme-inducing drugs. J Clin Pharmacol 1999; 39(6): 567–77PubMedCrossRef
196.
von Moltke LL, Greenblatt DJ, Harmatz JS, et al. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. J Pharmacol Exp Ther 1996; 276(2): 370–9
197.
Markowitz JS, DeVane CL, Boulton DW, et al. Effect of St John’s wort (Hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000; 66(9): PL133–9PubMedCrossRef
198.
Wang ZQ, Gorski C, Hamman MA, et al. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther 2001; 70(4): 317–26PubMed
199.
Dresser GK, Schwarz UI, Wilkinson GR, et al. Coordinate induction of both cytochrome P4503A and MDR1 by St John’s wort in healthy subjects. Clin Pharmacol Ther 2003; 73(1): 41–50PubMedCrossRef
200.
Burstein AH, Horton RL, Dunn T, et al. Lack of effect of St John’s wort on carbamazepine pharmacokinetics in healthy volunteers. Clin Pharmacol Ther 2000; 68(6): 605–12PubMedCrossRef
201.
Pelkonen O, Myllynen P, Taavitsainen P, et al. Carbamazepine: a ‘blind’ assessment of CYP-associated metabolism and interactions in human liver-derived in vitro systems. Xenobiotica 2001; 31(6): 321–43PubMedCrossRef
202.
Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism: Role of CYP3A4 and CYP2C8 in 10, 11-epoxide formation. Biochem Pharmacol 1994; 47(11): 1969–79PubMedCrossRef
203.
Tateishi T, Asoh M, Nakura H, et al. Carbamazepine induces multiple cytochrome P450 subfamilies in rats. Chem Biol Interact 1999; 117(3): 257–68PubMedCrossRef
204.
Kudriakova TB, Sirota LA, Rozova GI, et al. Autoinduction and steady-state pharmacokinetics of carbamazepine and its major metabolites. Br J Clin Pharmacol 1992; 33(6): 611–5PubMedCrossRef
205.
Owen A, Pirmohamed M, Tettey JN, et al. Carbamazepine is not a substrate for P-glycoprotein. Br J Clin Pharmacol 2001; 51(4): 345–9PubMedCrossRef
206.
Ohnishi N, Nakasako S, Okada K, et al. Studies on interactions between traditional herbal and western medicines. IV: lack of pharmacokinetic interactions between Saiko-ka-ryukotsuborei-to and carbamazepine in rats. Eur J Drug Metab Pharmacokinet 2001; 26(1–2): 129–35PubMedCrossRef
207.
Akhlaghi F, Trull AK. Distribution of cyclosporin in organ transplant recipients. Clin Pharmacokinet 2002; 41(9): 615–37PubMedCrossRef
208.
Lown KS, Mayo RR, Leichtman AB, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharm Ther 1997; 62(3): 248–60CrossRef
209.
Christians U, Strohmeyer S, Kownatzki R, et al. Investigations on the metabolic pathways of cyclosporine. II: elucidation of the metabolic pathways in vitro by human liver microsomes. Xenobiotica 1991; 21(9): 1199–210
210.
Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988; 43(6): 630–5PubMedCrossRef
211.
Combalbert J, Fabre I, Fabre G, et al. Metabolism of cyclosporin A. IV: purification and identification of the rifampicin-inducible human liver cytochrome P-450 (cyclosporin A oxidase) as a product of P450IIIA gene subfamily. Drug Metab Dispos 1989; 17(2): 197–207
212.
Jurima-Romet M, Crawford K, Cyr T, et al. Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 1994; 22(6): 849–57PubMed
213.
214.
Christians U, Strohmeyer S, Kownatzki R, et al. Investigations on the metabolic pathways of cyclosporine: I. Excretion of cyclosporine and its metabolites in human bile: isolation of 12 new cyclosporine metabolites. Xenobiotica 1991; 21(9): 1185–98
215.
Maurer G, Lemaire M. Biotransformation and distribution in blood of cyclosporine and its metabolites. Transplant Proc 1986; 18: 25–34PubMed
216.
Ruschitzka F, Meier PJ, Turina M, et al. Acute heart transplant rejection due to Saint John’s wort. Lancet 2000; 355(9203): 548–9PubMedCrossRef
217.
Barone GW, Gurley BJ, Ketel BL, et al. Drug interaction between St John’s wort and cyclosporine. Ann Pharmacother 2000; 34(9): 1013–6PubMedCrossRef
218.
Mai I, Kruger H, Budde K, et al. Hazardous pharmacokinetic interaction of Saint John’s wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther 2000; 38(10): 500–2PubMed
219.
Karliova M, Treichel U, Malago M, et al. Interaction of Hypericum perforatum (St John’s wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol 2000; 33(5): 853–5PubMedCrossRef
220.
Breidenbach T, Kliem V, Burg M, et al. Profound drop of cyclosporin A whole blood trough levels caused by St John’s wort (Hypericum perforatum). Transplantation 2000; 69(10): 2229–30PubMedCrossRef
221.
Bauer S, Stornier E, Johne A, et al. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John’s wort in renal transplant patients. Br J Clin Pharmacol 2003; 55(2): 203–11PubMedCrossRef
222.
Wieling J, Tamminga WJ, Sakiman EP, et al. Evaluation of analytical and clinical performance of a dual-probe phenotyping method for CYP2D6 polymorphism and CYP3A4 activity screening. Ther Drug Monit 2000; 22(4): 486–96PubMedCrossRef
223.
Bradford LD. CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 2002; 3(2): 229–43PubMedCrossRef
224.
Johne A, Brockmoller J, Bauer S, et al. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther 1999; 66(4): 338–45PubMedCrossRef
225.
Lacarelle B, Rahmani R, de Sousa G, et al. Metabolism of digoxin, digoxigenin digitoxosides and digoxigenin in human hepatocytes and liver microsomes. Fundam Clin Pharmacol 1991; 5(7): 567–82PubMedCrossRef
226.
Salphati L, Benet LZ. Metabolism of digoxin and digoxigenin digitoxosides in rat liver microsomes: involvement of cytochrome P4503A. Xenobiotica 1999; 29(2): 171–85PubMedCrossRef
227.
Durr D, Stieger B, Kullak-Ublick GA, et al. St John’s wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther 2000; 68: 598–604PubMedCrossRef
228.
Schinkel AH, Wagenaar E, van Deemter L, et al. Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A. J Clin Invest 1995; 96(4): 1698–705PubMedCrossRef
229.
Drescher S, Glaeser H, Murdter T, et al. P-glycoprotein-mediated intestinal and biliary digoxin transport in humans. Clin Pharmacol Ther 2003; 73(3): 223–31PubMedCrossRef
230.
Gault H, Longerich L, Dawe M, et al. Digoxin-rifampin interaction. Clin Pharmacol Ther 1984; 35(6): 750–4PubMedCrossRef
231.
Rameis H. On the interaction between phenytoin and digoxin. Eur J Clin Pharmacol 1985; 29(1): 49–53PubMedCrossRef
232.
Conseil G, Baubichon-Cortay H, Dayan G, et al. Flavonoids: a class of modulators with bifunctional interactions at vicinal ATP: and steroid-binding sites on mouse P-glycoprotein. Proc Natl Acad Sci U S A 1998; 95(17): 9831–6PubMedCrossRef
233.
234.
Cvetkovic M, Leake B, Fromm MF, et al. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metab Dispos 1999; 27(8): 866–71PubMed
235.
Tian R, Koyabu N, Takanaga H, et al. Effects of grapefruit juice and orange juice on the intestinal efflux of P-glycoprotein substrates. Pharm Res 2002; 19(6): 802–9PubMedCrossRef
236.
Lippert C, Ling J, Brown P, et al. Mass balance and pharmacokinetics of MDL 16455A in healthy male volunteers [abstract]. Pharm Res 1995; 12: S390
237.
Woosley RL, Chen Y, Freiman JP, et al. Mechanism of the cardiotoxic actions of terfenadine. JAMA 1993; 269: 1532–6PubMedCrossRef
238.
Wang ZQ, Hamman MA, Huang SM, et al. Effect of St John’s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther 2002; 71(6): 414–20PubMedCrossRef
239.
Johnson JR, Bross P, Cohen M, et al. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase. Clin Cancer Res 2003; 9(6): 1972–9PubMed
240.
Cohen MH, Williams G, Johnson JR, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002; 8(5): 935–42PubMed
241.
Cohen MH, Johnson JR, Pazdur R. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval. Clin Cancer Res 2005; 11(1): 12–9
242.
Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St John’s wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004; 76(4): 323–9PubMedCrossRef
243.
Smith P. The influence of St. John’s wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy 2004; 24(11): 1508–14
244.
Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004; 53(2): 102–6PubMedCrossRef
245.
Mathijssen RH, Verweij J, de Bruijn P, et al. Effects of St John’s wort on irinotecan metabolism. J Natl Cancer Inst 2002; 94(16): 1247–9PubMedCrossRef
246.
Eich-Hochli D, Oppliger R, Golay KP, et al. Methadone maintenance treatment and St John’s wort: a case report. Pharmacopsychiatry 2003; 36(1): 35–7PubMedCrossRef
247.
Moody DE, Alburges ME, Parker RJ, et al. The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos 1997; 25(12): 1347–53PubMed
248.
Wang JS, De Vane CL. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 2003; 31(6): 742–7PubMedCrossRef
249.
Borgelt-Hansen L. Oral contraceptives: an update on health benefits and risks. J Am Pharm Assoc (Wash) 2001; 41(6): 875–86
250.
Burkman RT, Collins JA, Shulman LP, et al. Current perspectives on oral contraceptive use. Am J Obstet Gynecol 2001; 185 (2 Suppl.): S4–12PubMedCrossRef
251.
Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. Annu Rev Pharmacol Toxicol 1998; 38: 389–430PubMedCrossRef
252.
Guengerich FP. Oxidation of 17-ethynylestradiol by human liver cytochrome P450. Mol Pharmacol 1988; 33(5): 500–8PubMed
253.
Murphy PA. St John’s wort and oral contraceptives: reasons for concern? J Midwifery Womens Health 2002; 47(6): 447–50PubMedCrossRef
254.
Shader RI, Greenblatt DJ. More on oral contraceptives, drug interactions, herbal medicines, and hormone replacement therapy. J Clin Psychopharmacol 2000; 20(4): 397–8PubMedCrossRef
255.
256.
Bolt HM. Interactions between clinically used drugs and oral contraceptives. Environ Health Perspect 1994; 102 Suppl. 9: 35–8PubMedCrossRef
257.
Yue QY, Bergquist C, Gerden B. Safety of St John’s wort (Hypericum perforatum). Lancet 2000; 355: 548–9CrossRef
258.
Schwarz UI, Buschel B, Kirch W. Unwanted pregnancy on self-medication with St John’s wort despite hormonal contraception. Br J Clin Pharmacol 2003; 55(2): 112–3PubMed
259.
Kaufeler R, Meier B, Brattstrom A. Ze 117: clinical efficacy and safety [abstract]. In: Roots I, Kemper FH, editors. Abstract book symposium on Phytopharmaka VII. Research and clinical applications. Berlin: Symposium Organising Committee, 2001 Oct 12–13
260.
Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St John’s wort. Lancet 2000; 355(9203): 547–8PubMedCrossRef
261.
Chiba M, Hensleigh M, Nishime JA, et al. Role of cytochrome P450 in human metabolism of MK-639, a potent human immunodeficiency virus protease inhibitor. Drug Metab Dispos 1996; 24: 307–14PubMed
262.
Decker CJ, Laitinen LM, Bridson GW, et al. Metabolism of amprenavir in liver microsomes: role of CYP3A4 inhibition for drug interactions. J Pharm Sci 1998; 87(7): 803–7PubMedCrossRef
263.
de Maat MM, Hoetelmans RM, Mathot RA, et al. Drug interaction between St John’s wort and nevirapine. AIDS 2001; 15(3): 420–1PubMedCrossRef
264.
Erickson DA, Mather G, Trager WF, et al. Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metab Dispos 1999; 27(12): 1488–95PubMed
265.
Kawaguchi A, Ohmori M, Tsuruoka S, et al. Drug interaction between St John’s Wort and quazepam. Br J Clin Pharmacol 2004; 58(4): 403–10PubMedCrossRef
266.
Vaswani M, Linda FK, Ramesh S. Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry 2003; 27(1): 85–102PubMedCrossRef
267.
Lantz MS, Buchalter E, Giambanco V. St John’s wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol 1999; 12(1): 7–10PubMedCrossRef
268.
Gordon JB. SSRIs and St John’s wort: possible toxicity? Am Fam Physician 1998; 57(5): 950–3PubMed
269.
Barbenel DM, Yusufi B, O’Shea D, et al. Mania in a patient receiving testosterone replacement postorchidectomy taking St John’s wort and sertraline. J Psychopharmacol 2000; 14(1): 84–6PubMedCrossRef
270.
Spinella M, Eaton LA. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj 2002; 16(4): 359–67PubMedCrossRef
271.
Dannawi M. Possible serotonin syndrome after combination of buspirone and St John’s wort [letter]. J Psychopharmacol 2002; 16(4): 401PubMedCrossRef
272.
Cookson J. Side-effects of antidepressants. Br J Psychiatry 1993; 163 Suppl. 20: 20–4
273.
Roz N, Mazur Y, Hirshfeld A, et al. Inhibition of vesicular uptake of monoamines by hyperforin. Life Sci 2002; 71(19): 2227–37PubMedCrossRef
274.
Wonnemann M, Singer A, Siebert B, et al. Evaluation of synaptosomal uptake inhibition of most relevant constituents of St John’s wort. Pharmacopsychiatry 2001; 34 Suppl. 1: S148–51PubMedCrossRef
275.
Butterweck V, Bockers T, Korte B, et al. Long-term effects of St John’s wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. Brain Res 2002; 930(1–2): 21–9PubMedCrossRef
276.
Nathan PJ. Hypericum perforatum (St John’s wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol 2001; 15(1): 47–54PubMedCrossRef
277.
Parker V, Wong AH, Boon HS, et al. Adverse reactions to St John’s wort. Can J Psychiatry 2001; 46(1): 77–9PubMed
278.
Beckman SE, Sommi RW, Switzer J. Consumer use of St John’s wort: a survey on effectiveness, safety, and tolerability. Pharmacotherapy 2000; 20(5): 568–74PubMedCrossRef
279.
Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St John’s Wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther 2001; 70(6): 518–24PubMedCrossRef
280.
Bolley R, Zulke C, Kammerl M, et al. Tacrolimus-induced nephrotoxicity unmasked by induction of the CYP3A4 system with St John’s wort [letter]. Transplantation 2002; 73(6): 1009PubMedCrossRef
281.
Mai I, Stornier E, Bauer S, et al. Impact of St John’s wort treatment on the pharmacokinetics of tacrolimus and mycophenolic acid in renal transplant patients. Nephrol Dial Transplant 2003; 18(4): 819–22PubMedCrossRef
282.
Nebel A, Schneider BJ, Baker RK, et al. Potential metabolic interaction between St John’s wort and theophylline [letter]. Ann Pharmacother 1999; 33(4): 502PubMedCrossRef
283.
Sarkar MA, Hunt C, Guzelian PS, et al. Characterization of human liver cytochromes P-450 involved in theophylline metabolism. Drug Metab Dispos 1992; 20(1): 31–7PubMed
284.
Maurer A, Johne A, Bauer S. Interaction of St John’s wort extract with phenprocoumon [abstract]. Eur J Clin Pharmacol 1999; 55: A22
285.
He M, Korzekwa KR, Jones JP, et al. Structural forms of phenprocoumon and warfarin that are metabolized at the active site of CYP2C9. Arch Biochem Biophys 1999; 372(1): 16–28PubMedCrossRef
286.
287.
Goodwin B, Moore LB, Stoltz CM, et al. Regulation of the human CYP2B6 gene by the nuclear pregnane X receptor. Mol Pharmacol 2001; 60(3): 427–31PubMed
288.
Wentworth JM, Agostini M, Love J, et al. St John’s wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166(3): R11–6PubMedCrossRef
289.
Bray BJ, Perry NB, Menkes DB, et al. St John’s wort extract induces CYP3A and CYP2E1 in the Swiss Webster mouse. Toxicol Sci 2002; 66(1): 27–33PubMedCrossRef
290.
Roby CA, Anderson GD, Kantor E, et al. St John’s wort: effect on CYP3A4 activity. Clin Pharmacol Ther 2000; 67(5): 451–7PubMedCrossRef
291.
Hennessy M, Kelleher D, Spiers JP, et al. St John’s wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol 2002; 53(1): 75–82PubMedCrossRef
292.
Perloff MD, von Moltke LL, Stornier E, et al. Saint John’s wort: an in vitro analysis of P-glycoprotein induction due to extended exposure. Br J Pharmacol 2001; 134(8): 1601–8PubMedCrossRef
293.
Xie R, Tan LH, Polasek EC, et al. CYP3A and P-glycoprotein activity induction with St. John’s wort in healthy volunteers from 6 ethnic populations. J Clin Pharmacol 2005; 45(3): 352–6
294.
Moschella C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St John’s wort) after organ transplantation. Am J Kidney Dis 2001; 38(5): 1105–7PubMedCrossRef
295.
296.
Bailey DG, Malcolm J, Arnold O, et al. Grapefruit juice-drug interactions. Br J Clin Pharmacol 1998; 46(2): 101–10PubMedCrossRef
297.
Hunter J, Hirst BH. Intestinal secretion of drugs: the role of p-glycoprotein and related drug efflux systems in limiting oral drug absorption. Adv Drug Deliver Rev 1997; 25: 129–57CrossRef
298.
Zhang YC, Benet LZ. The gut as a barrier to drug absorption: combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 2001; 40(3): 159–68PubMedCrossRef
299.
Wang MQ, Guilbert LJ, Ling L, et al. Immunomodulating activity of CVT-E002, a proprietary extract from North American ginseng (Panax quinquefolium). J Pharm Pharmacol 2001; 53(11): 1515–23PubMedCrossRef
300.
Liao BS, Newmark H, Zhou RP. Neuroprotective effects of ginseng total saponin and ginsenosides Rb1 and Rg1 on spinal cord neurons in vitro. Exp Neurol 2002; 173(2): 224–34PubMedCrossRef
301.
Deyama T, Nishibe S, Nakazawa Y. Constituents and pharmacological effects of Eucommia and Siberian ginseng. Acta Pharmacol Sin 2001; 22(12): 1057–70PubMed
302.
Chi JG. Cancer chemoprevention of INSAM (Ginseng): foreword [abstract]. J Korean Med Sci 2001; 16 Suppl. S: S1
303.
Nishino H, Tokuda H, Li T, et al. Cancer chemoprevention by ginseng in mouse liver and other organs. J Korean Med Sci 2001; 16 Suppl. S: S66–9PubMed
304.
Han BH, Han YN, Park MH, et al. Chemistry and biochemistry of ginseng components: ginsenosides and antioxidants. In: Mori A, Satoh A, editors. Emerging drugs: molecular aspects of Asian medicines. Singapore: World Scientific Publisher, 2001: 387–98
305.
Kitagawa I, Yoshikawa M, Yoshihara M, et al. Chemical studies of crude drugs (1): constituents of Ginseng radix rubra [in Japanese]. Yakugaku Zasshi 1983; 103: 612–22PubMed
306.
Bae EA, Han MJ, Choo MK, et al. Metabolism of 20 (S)- and 20 (R)-ginsenoside R-g3 by human intestinal bacteria and its relation to in vitro biological activities. Biol Pharm Bull 2002; 25(1): 58–63PubMedCrossRef
307.
Coon JT, Ernst E. Panax ginseng: a systematic review of adverse effects and drug interactions. Drug Saf 2002; 25(5): 323–44PubMedCrossRef
308.
Lee FC, Ko JH, Park JK, et al. Effects of Panax ginseng on blood alcohol clearance in man. Clin Exp Pharmacol Physiol 1987; 14(6): 543–6PubMedCrossRef
309.
Agarwal DP. Genetic polymorphisms of alcohol metabolizing enzymes. Pathol Biol (Paris) 2001; 49(9): 703–9CrossRef
310.
Ashmarin IP, Danilova RA, Obukhova MF, et al. Main ethanol metabolizing alcohol dehydrogenases (ADH I and ADH IV): biochemical functions and the physiological manifestation. FEBS Lett 2000; 486(1): 49–51PubMedCrossRef
311.
312.
Petkov V, Koushev V, Panova Y. Accelerated ethanol elimination under the effect of Ginseng (experiments on rats). Acta Physiol Pharmacol Bulg 1977; 3(1): 46–50PubMed
313.
Lee YJ, Pantuck CB, Pantuck EJ. Effect of ginseng on plasma levels of ethanol in the rat. Planta Med 1993; 59(1): 17–9PubMedCrossRef
314.
Shader RI, Greenblatt DJ. Phenelzine and the dream machine: ramblings and reflections. J Clin Psychopharmacol 1985; 5(2): 65PubMedCrossRef
315.
Jones BD, Runikis AM. Interaction of ginseng with phenelzine. J Clin Psychopharmacol 1987; 7(3): 201–2PubMedCrossRef
316.
Shader RI, Greenblatt DJ. Bees, ginseng and MAOIs revisited. J Clin Psychopharmacol 1988; 8(4): 235PubMedCrossRef
317.
Sala F, Mulet J, Choi S, et al. Effects of ginsenoside Rg2 on human neuronal nicotinic acetylcholine receptors. J Pharmacol Exp Ther 2002; 301(3): 1052–9PubMedCrossRef
318.
Toda N, Ayajiki K, Fujioka H, et al. Ginsenoside potentiates NO-mediated neurogenic vasodilatation of monkey cerebral arteries. J Ethnopharmacol 2001; 76(1): 109–13PubMedCrossRef
319.
Liu D, Li B, Liu Y, et al. Voltage-dependent inhibition of brain Na (+) channels by American ginseng. Eur J Pharmacol 2001: 413(1): 47–54PubMedCrossRef
320.
Kim S, Ahn K, Oh TH, et al. Inhibitory effect of ginsenosides on NMDA receptor-mediated signals in rat hippocampal neurons. Biochem Biophys Res Commun 2002; 296(2): 247–54PubMedCrossRef
321.
Baker GB, Urichuk LJ, McKenna KF, et al. Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol 1999; 19(3): 411–26PubMedCrossRef
322.
Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health Syst Pharm 1997; 54(6): 692–3PubMed
323.
Jiang X, Williams KM, Liauw WS, et al. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol 2004; 57(5): 592–9PubMedCrossRef
324.
Yuan CS, Wei G, Dey L, et al. Brief communication: American ginseng reduces warfarin’s effect in healthy patients: a randomized, controlled trial. Ann Intern Med 2004; 141(1): 23–7PubMed
325.
Cui X, Sakaguchi T, Shirai Y, et al. Orally administered Panax ginseng extract decreases platelet adhesiveness in 66% hepatectomized rats. Am J Chin Med 1999; 27(2): 251–6PubMedCrossRef
326.
Yun YP, Do JH, Ko SR, et al. Effects of Korean red ginseng and its mixed prescription on the high molecular weight dextraninduced blood stasis in rats and human platelet aggregation. J Ethnopharmacol 2001; 77(2–3): 259–64PubMedCrossRef
327.
Jung KY, Kim DS, Oh SR, et al. Platelet activating factor antagonist activity of ginsenosides. Biol Pharm Bull 1998; 21(1): 79–80PubMedCrossRef
328.
Kuo SC, Teng CM, Lee JC, et al. Antiplatelet components in Panax ginseng. Planta Med 1990; 56(2): 164–7PubMedCrossRef
329.
Zhu M, Chan KW, Ng LS, et al. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Pharm Pharmacol 1999; 51(2): 175–80PubMedCrossRef
330.
Nguyen TD, Villard PH, Barlatier A, et al. Panax vietnamensis protects mice against carbon tetrachloride-induced hepatotoxicity without any modification of CYP2E1 gene expression. Planta Med 2000; 66(8): 714–9PubMedCrossRef
331.
Chang TKH, Chen J, Benetton SA. In vitro effect of standardized ginseng extracts and individual ginsenosides on the catalytic activity of human CYP1A1, CYP1A2, and CYP1B1. Drug Metab Dispos 2002; 30(4): 378–84PubMedCrossRef
332.
Henderson GL, Harkey MR, Gershwin ME, et al. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 1999; 65(15): PL209–14PubMedCrossRef
333.
Furutsu M, Koyama Y, Kusakabe M, et al. Preventive effect of the extract of Du-zhong (Tochu) leaf and ginseng root on acute toxicity of chlorpyrifos. Jpn J Toxicol Environ Health 1997; 43(2): 92–100CrossRef
334.
Kim HJ, Chun YJ, Park JD, et al. Protection of rat liver micro-somes against carbon tetrachloride-induced lipid peroxidation by red ginseng saponin through cytochrome P450 inhibition. Planta Med 1997; 63(5): 415–8PubMedCrossRef
335.
Scaglione F, Cattaneo G, Alessandria M, et al. Efficacy and safety of the standardised Ginseng extract G115 for potentiating vaccination against the influenza syndrome and protection against the common cold [corrected; published erratum appears in Drugs Exp Clin Res 1996; 22 (6): 338]}. Drugs Exp Clin Res 1996; 22(2): 65–72PubMed
336.
Rivera E, Hu S, Concha C. Ginseng and aluminium hydroxide act synergistically as vaccine adjuvants. Vaccine 2003; 21(11–12): 1149–57PubMedCrossRef
337.
Hu S, Concha C, Lin F, et al. Adjuvant effect of ginseng extracts on the immune responses to immunisation against Staphylococcus aureus in dairy cattle. Vet Immunol Immunopathol 2003; 91(1): 29–37PubMedCrossRef
338.
Rivera E, Daggfeldt A, Hu S. Ginseng extract in aluminium hydroxide adjuvanted vaccines improves the antibody response of pigs to porcine parvovirus and Erysipelothrix rhusiopathiae. Vet Immunol Immunopathol 2003; 91(1): 19–27PubMedCrossRef
339.
Singh YN, Singh NN. Therapeutic potential of kava in the treatment of anxiety disorders. CNS Drugs 2002; 16(11): 731–43PubMedCrossRef
340.
Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders: a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 1997; 30(1): 1–5PubMedCrossRef
341.
Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. J Clin Psychopharmacol 2000; 20(2): 84–9PubMedCrossRef
342.
Rouse J. Kava: a South Pacific herb for anxiety, tension and insomnia. Clin Nutr Insights 1998; 96: 3900–5
343.
Wheatley D. Stress-induced insomnia treated with kava and valerian: singly and in combination. Hum Psychopharmacol 2001; 16(4): 353–6PubMedCrossRef
344.
Stevinson C, Huntley A, Ernst E. A systematic review of the safety of kava extract in the treatment of anxiety. Drug Saf 2002; 25(4): 251–61PubMedCrossRef
345.
Bilia AR, Gallon S, Vincieri FF. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Life Sci 2002; 70(22): 2581–97PubMedCrossRef
346.
Lebot V, Lévesque J. The origin and distribution of kava (Piper methysticum Forst, f. and Piper wichmannii C. DC, Piperaceae): a phytochemical approach. Allertonia 1989; 5: 223–80
347.
Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci 2002; 71(13): 1579–89PubMedCrossRef
348.
Anke J, Ramzan I. Pharmacokinetic and pharmacodynamic drug interactions with Kava (Piper methysticum Forst, f.) J Ethnopharmacol 2004; 93(2–3): 153–60PubMedCrossRef
349.
Herberg KW. Effect of Kava-Special Extract WS 1490 combined with ethyl alcohol on safety-relevant performance parameters [in German]. Blutalkohol 1993; 30(2): 96–105PubMed
350.
Jamieson DD, Duffield PH. Positive interaction of ethanol and kava resin in mice. Clin Exp Pharmacol Physiol 1990; 17(7): 509–14PubMedCrossRef
351.
Almeida JC, Grimsley EW. Coma from the health food store: interaction between Kava and alprazolam. Ann Intern Med 1996; 125(11): 940–1PubMed
352.
Yuan CS, Dey L, Wang A, et al. Kavalactones and dihydrokavain modulate GABAergic activity in a rat gastric-brainstem preparation. Planta Med 2002; 68(12): 1092–6PubMedCrossRef
353.
Jussofie A, Schmiz A, Hiemke C. Kavapyrone enriched extract from Piper methysticum as modulator of the GABA binding site in different regions of rat brain. Psychopharmacology (Berl) 1994; 116(4): 469–74PubMedCrossRef
354.
Gorski JC, Jones DR, Hamman MA, et al. Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica 1999; 29(9): 931–44PubMedCrossRef
355.
Herberg KW. Safety-related performance after intake of kava-extract, bromazepam and their combination. Z Allgemeinmed 1996; 72: 973–7
356.
Schelosky L, Raffauf C, Jendroska K, et al. Kava and dopamine antagonism. J Neurol Neurosurg Psychiatry 1995; 58(5): 639–40PubMedCrossRef
357.
Baum SS, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the nucleus accumbens of rats. Prog Neuropsychopharmacol Biol Psychiatry 1998; 22(7): 1105–20PubMedCrossRef
358.
Meseguer E, Taboada R, Sanchez V, et al. Life-threatening parkinsonism induced by kava-kava. Mov Disord 2002; 17(1): 195–6PubMedCrossRef
359.
Bajad S, Bedi KL, Singla AK, et al. Piperine inhibits gastric emptying and gastrointestinal transit in rats and mice. Planta Med 2001; 67(2): 176–9PubMedCrossRef
360.
Hiwale AR, Dhuley JN, Naik SR. Effect of co-administration of piperine on pharmacokinetics of beta-lactam antibiotics in rats. Indian J Exp Biol 2002; 40(3): 277–81PubMed
361.
Gupta SK, Bansal P, Bhardwaj RK, et al. Comparative anti-nociceptive, anti-inflammatory and toxicity profile of nimesulide vs nimesulide and piperine combination. Pharm Res 2000; 41(6): 657–62CrossRef
362.
Mujumdar AM, Dhuley JN, Deshmukh VK, et al. Effect of piperine on pentobarbitone induced hypnosis in rats. Indian J Exp Biol 1990; 28(5): 486–7PubMed
363.
Shoba G, Joy D, Joseph T, et al. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 1998; 64(4): 353–6PubMedCrossRef
364.
Badmaev VV, Majeed M, Prakash L. Piperine derived from black pepper increases the plasma levels of coenzyme q10 following oral supplementation. J Nutr Biochem 2000; 11(2): 109–13PubMedCrossRef
365.
Bano G, Raina RK, Zutshi U, et al. Effect of piperine on bioavailability and pharmacokinetics of propranolol and theophylline in healthy volunteers. Eur J Clin Pharmacol 1991; 41(6): 615–7PubMedCrossRef
366.
Johnson JA, Herring VL, Wolfe MS, et al. CYP1A2 and CYP2D6 4-hydroxylate propranolol and both reactions exhibit racial differences. J Pharmacol Exp Ther 2000; 294(3): 1099–105PubMed
367.
Ching MS, Bichara N, Blake CL, et al. Propranolol 4- and 5-hydroxylation and N-desisopropylation by cloned human cytochrome P4501A1 and P4501A2. Drug Metab Dispos 1996; 24(6): 692–4PubMed
368.
Yoshimoto K, Echizen H, Chiba K, et al. Identification of human CYP isoforms involved in the metabolism of propranolol enantiomers: N-desisopropylation is mediated mainly by CYP1A2. Br J Clin Pharmacol 1995; 39(4): 421–31PubMedCrossRef
369.
Singh J, Reen RK. Modulation of constitutive, benz[a]anthracene- and phenobarbital-inducible cytochromes-P450 activities in rat hepatoma H4IIEC3/G-cells by piperine. Curr Sci 1994; 66(5): 365–9
370.
Dalvi RR, Dalvi PS. Comparison of the effects of piperine administered intragastrically and intraperitoneally on the liver and liver mixed-function oxidases in rats. Drug Metabol Drug Interact 1991; 9(1): 23–30PubMedCrossRef
371.
Kang MH, Won SM, Park SS, et al. Piperine effects on the expression of P4502E1, P4502B and P4501A in rat. Xenobiotica 1994; 24(12): 1195–204PubMedCrossRef
372.
Zutshi RK, Singh R, Zutshi U, et al. Influence of piperine on rifampicin blood levels in patients of pulmonary tuberculosis. J Assoc Physicians India 1985; 33: 223–4PubMed
373.
Schuetz EG, Schinkel AH, Relling MV, et al. P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans. Proc Natl Acad Sci U S A 1996; 93: 4001–5PubMedCrossRef
374.
Bhardwaj RK, Glaeser H, Becquemont L, et al. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 302(2): 645–50PubMedCrossRef
375.
Atal CK, Zutshi U, Rao PG. Scientific evidence on the role of Ayurvedic herbals on bioavailability of drugs. J Ethnopharmacol 1981; 4: 229–32PubMedCrossRef
376.
Dalvi RR, Dalvi PS. Differences in the effects of piperine and piperonyl butoxide on hepatic drug-metabolizing enzyme system in rats. Drug Chem Toxicol 1991; 14(1–2): 219–29PubMedCrossRef
377.
Tjia JF, Colbert J, Back DJ. Theophylline metabolism in human liver microsomes: inhibition studies. J Pharmacol Exp Ther 1996; 276(3): 912–7PubMed
378.
Ha HR, Chen J, Freiburghaus AU, et al. Metabolism of theophylline by cDNA-expressed human cytochromes P-450. Br J Clin Pharmacol 1995; 39(3): 321–6PubMedCrossRef
379.
Velpandian T, Jasuja R, Bhardwaj RK, et al. Piperine in food: interference in the pharmacokinetics of phenytoin. Eur J Drug Metab Pharmacokinet 2001; 26(4): 241–7PubMedCrossRef
380.
Bano G, Amla V, Raina RK, et al. The effect of piperine on pharmacokinetics of phenytoin in healthy volunteers. Planta Med 1987; 53(6): 568–9PubMedCrossRef
381.
Tsukamoto S, Cha BC, Ohta T. Dipiperamides A, B, and C: bisalkaloids from the white pepper Piper nigrum inhibiting CYP3A4 activity. Tetrahedron 2002; 58(9): 1667–71CrossRef
382.
Veronese ME, Mackenzie PI, Doecke CJ, et al. Tolbutamide and phenytoin hydroxylations by cDNA-expressed human liver cytochrome P4502C9. Biochem Biophys Res Commun 1991; 175(3): 1112–8PubMedCrossRef
383.
Bajpai M, Roskos LK, Shen DD, et al. Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 1996; 24(12): 1401–14PubMed
384.
Cuttle L, Munns AJ, Hogg NA, et al. Phenytoin metabolism by human cytochrome P450: involvement of P450 3A and 2C forms in secondary metabolism and drug-protein adduct formation. Drug Metab Dispos 2000; 28(8): 945–50PubMed
385.
Munns AJ, De Voss JJ, Hooper WD, et al. Bioactivation of phenytoin by human cytochrome P450: characterization of the mechanism and targets of covalent adduct formation. Chem Res Toxicol 1997; 10(9): 1049–58PubMedCrossRef
386.
Komatsu T, Yamazaki H, Asahi S, et al. Formation of a dihydroxy metabolite of phenytoin in human liver microsomes/cytosol: roles of cytochromes P4502C9, 2C19, and 3A4. Drug Metab Dispos 2000; 28(11): 1361–8PubMed
387.
Schinkel AH, Wagenaar E, Mol CA, et al. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J Clin Invest 1996; 97: 2517–24PubMedCrossRef
388.
Cummins CL, Jacobsen W, Benet LZ. Unmasking the dynamic interplay between intestinal P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 2002; 300(3): 1036–45PubMedCrossRef
389.
Ji XY, Tan BK, Zhu YZ. Salvia miltiorrhiza and ischemic diseases. Acta Pharmacol Sin 2000; 21(12): 1089–94PubMed
390.
Lee AR, Wu WL, Chang WL, et al. Isolation and bioactivity of new tanshinones. J Nat Prod 1987; 50(2): 157–60PubMedCrossRef
391.
Chan TY. Interaction between warfarin and danshen (Salvia miltiorrhiza). Ann Pharmacother 2001; 35(4): 501–4PubMedCrossRef
392.
Yu CM, Chan JC, Sanderson JE. Chinese herbs and warfarin potentiation by ‘danshen’. J Intern Med 1997; 241(4): 337–9PubMedCrossRef
393.
Au-Yeung KK, Zhu DY, O K, et al. Inhibition of stress-activated protein kinase in the ischemic/reperfused heart: role of magnesium tanshinoate B in preventing apoptosis. Biochem Pharmacol 2001; 62(4): 483–93PubMedCrossRef
394.
Zhou W, Ruigrok TJ. Protective effect of danshen during myocardial ischemia and reperfusion: an isolated rat heart study. Am J Chin Med 1990; 18(1–2): 19–24PubMedCrossRef
395.
Wu TW, Zeng LH, Fung KP, et al. Effect of sodium tanshinone IIA sulfonate in the rabbit myocardium and on human cardiomyocytes and vascular endothelial cells. Biochem Pharmacol 1993; 46(12): 2327–32PubMedCrossRef
396.
Kim SY, Moon TC, Chang HW, et al. Effects of tanshinone I isolated from Salvia miltiorrhiza bunge on arachidonic acid metabolism and in vivo inflammatory responses. Phytother Res 2002; 16(7): 616–20PubMedCrossRef
397.
Oh SH, Nan JX, Sohn DW, et al. Salvia miltiorrhiza inhibits biliary obstruction-induced hepatocyte apoptosis by cytoplasmic sequestration of p53. Toxicol Appl Pharmacol 2002; 182(1): 27–33PubMedCrossRef
398.
Lee TY, Mai LM, Wang GJ, et al. Protective mechanism of Salvia miltiorrhiza on carbon tetrachloride-induced acute hepatotoxicity in rats. J Pharmacol Sci 2003; 91(3): 202–10PubMedCrossRef
399.
Peng Y, Liu F, Luo J, et al. Effects of danshen and shengmaiye on glomerulosclerosis by adriamycin in rats [in Chinese]. Hunan Yi Ke Da Xue Xue Bao 1999; 24(4): 332–4PubMed
400.
Sato M, Sato T, Ose Y, et al. Modulating effect of tanshinones on mutagenic activity of Trp-P-1 and benzo[a]pyrene in Salmonella typhimurium. Mutat Res 1992; 265(2): 149–54PubMedCrossRef
401.
Abd-Elazem IS, Chen HS, Bates RB, et al. Isolation of two highly potent and non-toxic inhibitors of human immunodeficiency virus type 1 (HIV-1) integrase from Salvia miltiorrhiza. Antiviral Res 2002; 55(1): 91–106PubMedCrossRef
402.
Kang BY, Chung SW, Kim SH, et al. Inhibition of interleukin-12 and interferon-gamma production in immune cells by tanshinones from Salvia miltiorrhiza. Immunopharmacology 2000; 49(3): 355–61PubMedCrossRef
403.
Ryu SY, Oak MH, Kim KM. Inhibition of mast cell degranulation by tanshinones from the roots of Salvia miltiorrhiza. Planta Med 1999; 65(7): 654–5PubMedCrossRef
404.
O K, Lynn EG, Vazhappilly R, et al. Magnesium tanshinoate B (MTB) inhibits low density lipoprotein oxidation. Life Sci 2001; 68(8): 903–12PubMedCrossRef
405.
Zhao BL, Jiang W, Zhao Y, et al. Scavenging effects of salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Biochem Mol Biol Int 1996; 38(6): 1171–82PubMed
406.
Kang DG, Yun YG, Ryoo JH, et al. Anti-hypertensive effect of water extract of danshen on renovascular hypertension through inhibition of the renin angiotensin system. Am J Chin Med 2002; 30(1): 87–93PubMedCrossRef
407.
Wang GZ, Ru X, Ding LH, et al. Short term effect of Salvia miltiorrhiza in treating rat acetic acid chronic gastric ulcer and long term effect in preventing recurrence. World J Gastroenterol 1998; 4(2): 169–70PubMed
408.
Lay IS, Chiu JH, Shiao MS, et al. Crude extract of Salvia miltiorrhiza and salvianolic acid B enhance in vitro angiogenesis in murine SVR endothelial cell line. Planta Med 2003; 69(1): 26–32PubMedCrossRef
409.
Liu J, Shen HM, Ong CN. Role of intracellular thiol depletion, mitochondrial dysfunction and reactive oxygen species in Salvia miltiorrhiza-induced apoptosis in human hepatoma HepG2 cells. Life Sci 2001; 69(16): 1833–50PubMedCrossRef
410.
Wu WL, Chang WL, Chen CF. Cytotoxic activities of tanshinones against human carcinoma cell lines. Am J Chin Med 1991; 19(3–4): 207–16PubMedCrossRef
411.
412.
Cheng TO. Warfarin danshen interaction [letter]. Ann Thorac Surg 1999; 67(3): 894PubMed
413.
Lo AC, Chan K, Yeung JH, et al. The effects of danshen (Salvia miltiorrhiza) on pharmacokinetics and pharmacodynamics of warfarin in rats. Eur J Drug Metab Pharmacokinet 1992; 17(4): 257–62PubMedCrossRef
414.
Petitpas I, Bhattacharya AA, Twine S, et al. Crystal structure analysis of warfarin binding to human serum albumin: anatomy of drug site I. J Biol Chem 2001; 276(25): 22804–9PubMedCrossRef
415.
Fitos I, Visy J, Kardos J. Stereoselective kinetics of warfarin binding to human serum albumin: effect of an allosteric interaction. Chirality 2002; 14(5): 442–8PubMedCrossRef
416.
Gupta D, Jalali M, Wells A, et al. Drug-herb interactions: unexpected suppression of free Danshen concentrations by salicylate. J Clin Lab Anal 2002; 16(6): 290–4PubMedCrossRef
417.
Makino T, Wakushima H, Okamoto T, et al. Pharmacokinetic interactions between warfarin and kangen-karyu, a Chinese traditional herbal medicine, and their synergistic action. J Ethnopharmacol 2002; 82(1): 35–40PubMedCrossRef
418.
Tang W, Eisenbrand G. Scutellaria baicalensis Georgi: Chinese drugs of plant original. Heidelberg: Springer-Verlag, 1992CrossRef
419.
Qi L, Zhou R, Wang YF, et al. Study of major flavonoids in crude Scutellariae Radix by micellar electrokinetic capillary chromatography. J Capillary Electrophor 1998; 5(5–6): 181–4PubMed
420.
Taniguchi C, Homma M, Takano O, et al. Pharmacological effects of urinary products obtained after treatment with saiboku-to, a herbal medicine for bronchial asthma, on type IV allergic reaction. Planta Med 2000; 66(7): 607–11PubMedCrossRef
421.
Hou YN, Zhu XY, Cheng GF. Effects of baicalin on liver microsomal cytochrome P450 system [in Chinese]. Yao Xue Xue Bao 2000; 35(12): 890–2PubMed
422.
Lin CC, Shieh DE. The anti-inflammatory activity of Scutellaria rivularis extracts and its active components, baicalin, baicalein and wogonin. Am J Chin Med 1996; 24(1): 31–6PubMedCrossRef
423.
Shieh DE, Liu LT, Lin CC. Antioxidant and free radical scavenging effects of baicalein, baicalin and wogonin. Anticancer Res 2000; 20(5A): 2861–5PubMed
424.
Gao Z, Huang K, Yang X, et al. Free radical scavenging and antioxidant activities of flavonoids extracted from the radix of Scutellaria baicalensis Georgi. Biochim Biophys Acta 1999; 1472(3): 643–50PubMedCrossRef
425.
Ikemoto S, Sugimura K, Yoshida N, et al. Antitumor effects of Scutellariae radix and its components baicalein, baicalin, and wogonin on bladder cancer cell lines. Urology 2000; 55(6): 951–5PubMedCrossRef
426.
Akao T, Kawabata K, Yanagisawa E, et al. Baicalin, the predominant flavone glucuronide of scutellariae radix, is absorbed from the rat gastrointestinal tract as the aglycone and restored to its original form. J Pharm Pharmacol 2000; 52(12): 1563–8PubMedCrossRef
427.
Wakui Y, Yanagisawa E, Ishibashi E, et al. Determination of baicalin and baicalein in rat plasma by high-performance liquid chromatography with electrochemical detection. J Chromatogr 1992; 575(1): 131–6PubMedCrossRef
428.
Lai MY, Hsiu SL, Tsai SY, et al. Comparison of metabolic pharmacokinetics of baicalin and baicalein in rats. J Pharm Pharmacol 2003; 55(2): 205–9PubMedCrossRef
429.
Lai MY, Hsiu SL, Chen CC, et al. Urinary pharmacokinetics of baicalein, wogonin and their glycosides after oral administration of Scutellariae Radix in humans. Biol Pharm Bull 2003; 26(1): 79–83PubMedCrossRef
430.
Canal P, Gay C, Dezeuze A, et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer: Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1996; 14(10): 2688–95PubMed
431.
Gupta E, Mick R, Ramirez J, et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997; 15(4): 1502–10PubMed
432.
Kudoh S, Fujiwara Y, Takada Y, et al. Phase II study of irinotecan combined with cisplatin in patients with previously untreated small-cell lung cancer. West Japan Lung Cancer Group. J Clin Oncol 1998; 16(3): 1068–74
433.
Humerickhouse R, Lohrbach K, Li L, et al. Characterization of CPT-11 hydrolysis by human liver carboxylesterase isoforms hCE-1 and hCE-2. Cancer Res 2000; 60(5): 1189–92PubMed
434.
Bencharit S, Morton CL, Howard-Williams EL, et al. Structural insights into CPT-11 activation by mammalian carboxylesterases. Nat Struct Biol 2002; 9(5): 337–42PubMedCrossRef
435.
Rivory LP, Bowles MR, Robert J, et al. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxy-camptothecin (SN-38), by human liver carboxylesterase. Biochem Pharmacol 1996; 52(7): 1103–11PubMedCrossRef
436.
Hanioka N, Ozawa S, Jinno H, et al. Human liver UDP-glucuronosyltransferase isoforms involved in the glucuronidation of 7-ethyl-10-hydroxycamptothecin. Xenobiotica 2001; 31(10): 687–99PubMedCrossRef
437.
Mathijssen RHJ, van Alphen RJ, Verweij J, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001; 7(8): 2182–94PubMed
438.
Santos A, Zanetta S, Cresteil T, et al. Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000; 6(5): 2012–20PubMed
439.
Sugiyama Y, Kato Y, Chu X. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. Cancer Chemother Pharmacol 1998; 42 Suppl.: S44–9PubMedCrossRef
440.
Gupta E, Lestingi TM, Mick R, et al. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res 1994; 54(14): 3723–5PubMed
441.
Xie R, Mathijssen RH, Sparreboom A, et al. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea. Clin Pharmacol Ther 2002; 72(3): 265–75PubMedCrossRef
442.
Mori K, Kondo T, Kamiyama Y, et al. Preventive effect of Kampo medicine (Hangeshashin-to) against irinotecan-induced diarrhea in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 2003; 51(5): 403–6PubMed
443.
Takasuna K, Kasai Y, Kitano Y, et al. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats. Jpn J Cancer Res 1995; 86(10): 978–84PubMedCrossRef
444.
Kase Y, Hayakawa T, Aburada M, et al. Preventive effects of Hange-shashin-to on irinotecan hydrochloride-caused diarrhea and its relevance to the colonic prostaglandin E2 and water absorption in the rat. Jpn J Pharmacol 1997; 75(4): 407–13PubMedCrossRef
445.
Kase Y, Hayakawa T, Togashi Y, et al. Relevance of irinotecan hydrochloride-induced diarrhea to the level of prostaglandin E2 and water absorption of large intestine in rats. Jpn J Pharmacol 1997; 75(4): 399–405PubMedCrossRef
446.
Narita M, Nagai E, Hagiwara H, et al. Inhibition of betaglucuronidase by natural glucuronides of kampo medicines using glucuronide of SN-38 (7-ethyl-10-hydroxy-camptothecin) as a substrate. Xenobiotica 1993; 23(1): 5–10PubMedCrossRef
447.
Chu XY, Suzuki H, Ueda K, et al. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. J Pharmacol Exp Ther 1999; 288(2): 735–41PubMed
448.
Chu XY, Kato Y, Ueda K, et al. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. Cancer Res 1998; 58(22): 5137–43PubMed
449.
Chu XY, Kato Y, Niinuma K, et al. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. J Pharmacol Exp Ther 1997; 281(1): 304–14PubMed
450.
Wallace S, Carrier D, Clausen E. Extraction of nutraceuticals from milk thistle: part II. Extraction with organic solvents. Appl Biochem Biotechnol 2003; 108(1–3): 891–904CrossRef
451.
Barreto J, Wallace S, Carrier D, et al. Extraction of nutraceuticals from milk thistle. I: hot water extraction. Appl Biochem Biotechnol 2003; 108(1–3): 881–90CrossRef
452.
Wellington K, Jarvis B. Silymarin: a review of its clinical properties in the management of hepatic disorders. Biodrugs 2001; 15(7): 465–89PubMedCrossRef
453.
Quaglia MG, Bossu E, Donati E, et al. Determination of silymarine in the extract from the dried silybum marianum fruits by high performance liquid chromatography and capillary electrophoresis. J Pharm Biomed Anal 1999; 19(3–4): 435–42PubMedCrossRef
454.
Kvasnicka F, Biba B, Sevcik R, et al. Analysis of the active components of silymarin. J Chromatogr A 2003; 990(1–2): 239–45PubMed
455.
Ding T, Tian S, Zhang Z, et al. Determination of active component in silymarin by RP-LC and LC/MS. J Pharm Biomed Anal 2001; 26(1): 155–61PubMedCrossRef
456.
Lorenz D. Untersuchungen zur elimination von silymarin bei cholezystektomiertan patientsten 2. Mitteilung: Biliaere elimination nach mehrfacher oraler Gabe. Planta Med 1982; 45: 216–23
457.
Kren V, Ulrichova J, Kosina P, et al. Chemoenzymatic preparation of silybin beta-glucuronides and their biological evaluation. Drug Metab Dispos 2000; 28(12): 1513–7PubMed
458.
Weyhenmeyer R, Mascher H, Birkmayer J. Study on doselinearity of the pharmacokinetics of silibinin diastereomers using a new stereospecific assay. Int J Clin Pharmacol Ther Toxicol 1992; 30(4): 134–41PubMed
459.
Gatti G, Perucca E. Plasma concentrations of free and conjugated silybin after oral intake of a silybin-phosphatidylcholine complex (silipide) in healthy volunteers. Int J Clin Pharmacol Ther 1994; 32(1): 614–7PubMed
460.
Schandalik R, Gatti G, Perucca E. Pharmacokinetics of silybin in bile following administration of silipide and silymarin in cholecystectomy patients. Arzneimittelforschung 1992; 42(7): 964–8PubMed
461.
Salmi HA, Sarna S. Effects of silymarin on chemical functional and morphological alterations of the liver. Scand J Gastroenterol 1982; 17: 517–21PubMedCrossRef
462.
Piscitelli SC, Formentini E, Burstein AH, et al. Effect of milk thistle on the pharmacokinetics of indinavir in healthy volunteers. Pharmacotherapy 2002; 22(5): 551–6PubMedCrossRef
463.
DiCenzo R, Shelton M, Jordan K, et al. Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy 2003; 23(7): 866–70PubMedCrossRef
464.
Beckmann-Knopp S, Rietbrock S, Weyhenmeyer R, et al. Inhibitory effects of silibinin on cytochrome P-450 enzymes in human liver microsomes. Pharmacol Toxicol 2000; 86(6): 250–6PubMedCrossRef
465.
Venkataramanan R, Ramachandran V, Komoroski BJ, et al. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronosyl transferase in human hepatocyte cultures. Drug Metab Dispos 2000; 28(11): 1270–3PubMed
466.
Sridar C, Goosen TC, Kent UM, et al. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004; 32(6): 587–94PubMedCrossRef
467.
Schandalik R, Perucca E. Pharmacokinetics of silybin following oral administration of silipide in patients with extrahepatic biliary obstruction. Drugs Exp Clin Res 1994; 20(1): 37–42PubMed
468.
Gurley BJ, Gardner SF, Hubbard MA, et al. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther 2004; 76(5): 428–40PubMedCrossRef
469.
Zhang S, Morris ME. Effects of the flavonoids biochanin A, morin, phloretin, and silymarin on P-glycoprotein-mediated transport. J Pharmacol Exp Ther 2003; 304(3): 1258–67PubMedCrossRef
470.
Tyagi AK, Singh RP, Agarwal C, et al. Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth Inhibition, G2-M arrest, and apoptosis. Clin Cancer Res 2002; 8(11): 3512–9PubMed
471.
Maitrejean M, Comte G, Barron D, et al. The flavanolignan silybin and its hemisynthetic derivatives, a novel series of potential modulators of P-glycoprotein. Bioorg Med Chem Lett 2000; 10(2): 157–60PubMedCrossRef
472.
Schlichting J, Leuschner U. Drug therapy of primary biliary diseases: classical and modern strategies. J Cell Mol Med 2001; 5(1): 98–115PubMedCrossRef
473.
Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002; 36(3): 525–31PubMedCrossRef
474.
Angulo P, Patel T, Jorgensen RA, et al. Silymarin in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology 2000; 32(5): 897–900PubMedCrossRef
475.
Ellis GR, Stephens MR. Untitled [photograph and brief case report]. BMJ 1999; 319: 650CrossRef
476.
Deahl M. Betel nut-induced extrapyramidal syndrome: an unusual drug interaction. Mov Disord 1989; 4(4): 330–2PubMedCrossRef
477.
Mathews Jr MK. Association of Ginkgo biloba with intracerebral haemorrhage [letter]. Neurology 1998; 50(6): 1933–4CrossRef
478.
Rey JM, Walter G. Hypericum perforatum (St John’s wort) in depression: pest or blessing? Med J Aust 1998; 169(11–12): 583–6PubMed
479.
Bon S, Hartmann K, Kubn M. Johanniskraut: ein enzyminduktor? Schweitz Apoth Ztg 1999; 16: 535–6
480.
Breidenbach T, Hoffmann MW, Becker T, et al. Drug interaction of St John’s wort with cyclosporin [letter]. Lancet 2000: 355(9218): 1912PubMedCrossRef
481.
Roots I, Johne A, Maurer A. Arzneimittel interaktionen von hypericum-extract [abstract]. In: Roots I, Kemper FH, editors. Proc Germ Soc Pharmacol. Berlin: Conference Organising Committee, 2000 Jun 16–17
482.
Barone GW, Gurley BJ, Ketel BL, et al. Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation 2001; 71(2): 239–41PubMedCrossRef
483.
Khawaja IS, Marotta RF, Lippmann S. Herbal medicines as a factor in delirium. Psychiatr Serv 1999; 50(7): 969–70PubMed
484.
Valenzuela A, Bustamante JC, Videla C, et al. Effect of silybin dihemisuccinate on the ethanol metabolizing systems of the rat liver. Cell Biochem Funct 1989; 7(3): 173–8PubMedCrossRef
485.
Comoglio A, Tomasi A, Malandrino S, et al. Scavenging effect of silipide, a new silybin-phospholipid complex, on ethanol-derived free radicals. Biochem Pharmacol 1995; 50(8): 1313–6PubMedCrossRef
486.
Varga M, Buris L, Fodor M. Ethanol elimination in man under influence of hepatoprotective silibinin. Blutalkohol 1991; 28(6): 405–8PubMed
487.
Gyonos I, Agoston M, Kovacs A, et al. Silymarin and vitamin E do not attenuate and vitamin E might even enhance the antiarrhythmic activity of amiodarone in a rat reperfusion arrhythmia model. Cardiovasc Drugs Ther 2001; 15(3): 233–40PubMedCrossRef
488.
Gill J, Heel RC, Fitton A. Amiodarone: an overview of its pharmacological properties, and review of its therapeutic use in cardiac arrhythmias. Drugs 1992; 43(1): 69–110PubMedCrossRef
489.
Trivier J–M, Libersa C, Belloc C, et al. Amiodarone N-deethylation in human liver microsomes: involvement of cytochrome P4503A enzymes (first report). Life Sci 1993; 52(10): 91–6
490.
Fabre G, Julian B, Saint-Aubert B, et al. Evidence for CYP3A-mediated N-deethylation of amiodarone in human liver microsomal fractions. Drug Metab Dispos 1993; 21(6): 978–85PubMed
491.
Ohyama K, Nakajima M, Nakamura S, et al. A significant role of human cytochrome P4502C8 in amiodarone N-deethylation: an approach to predict the contribution with relative activity factor. Drug Metab Dispos 2000; 28(11): 1303–10PubMed
492.
Scambia G, De Vincenzo R, Ranelletti FO, et al. Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin. Eur J Cancer 1996; 32A(5): 877–82PubMedCrossRef
493.
Giacomelli S, Gallo D, Apollonio P, et al. Silybin and its bioavailable phospholipid complex (IdB 1016) potentiate in vitro and in vivo the activity of cisplatin. Life Sci 2002; 70(12): 1447–59PubMedCrossRef
494.
Bokemeyer C, Fels LM, Dunn T, et al. Silibinin protects against cisplatin-induced nephrotoxicity without compromising cisplatin or ifosfamide anti-tumour activity. Br J Cancer 1996; 74(12): 2036–41PubMedCrossRef
495.
Gaedeke J, Fels LM, Bokemeyer C, et al. Cisplatin nephrotoxicity and protection by silibinin. Nephrol Dial Transplant 1996: 11(1): 55–62PubMedCrossRef
496.
Shelley MD, Burgon K, Mason MD. Treatment of testicular germ-cell cancer: a cochrane evidence-based systematic review. Cancer Treat Rev 2002; 28(5): 237–53PubMedCrossRef
497.
Sandercock J, Parmar MK, Torri V, et al. First-line treatment for advanced ovarian cancer: paclitaxel, platinum and the evidence. Br J Cancer 2002; 87(8): 815–24PubMedCrossRef
498.
Piccart MJ, Lamb H, Vermorken JB. Current and future potential roles of the platinum drugs in the treatment of ovarian cancer. Ann Oncol 2001; 12(9): 1195–203PubMedCrossRef
499.
Go RS, Adjei AA. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J Clin Oncol 1999; 17(1): 409–22PubMed
500.
Zima T, Kamenikova L, Janebova M, et al. The effect of silibinin on experimental cyclosporine nephrotoxicity. Ren Fail 1998; 20(3): 471–9PubMedCrossRef
501.
von Schonfeld J, Weisbrod B, Muller MK. Silibinin, a plant extract with antioxidant and membrane stabilizing properties, protects exocrine pancreas from cyclosporin A toxicity. Cell Mol Life Sci 1997; 53(11–12): 917–20CrossRef
502.
Dresser GK, Spence JD, Bailey DG. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition. Clin Pharmacokinet 2000; 38(1): 41–57PubMedCrossRef
503.
Zhou S, Gao Y, Jiang W, et al. Interactions of herbs with cytochrome P450. Drug Metab Rev 2003; 35(1): 35–98PubMedCrossRef
504.
Zhou S, Lim LY, Chowbay B. Herbal modulation of P-glycoprotein. Drug Metab Rev 2004; 36(1): 57–104PubMedCrossRef
505.
Zhou S, Chan E, Li SC, et al. Predicting pharmacokinetic herbdrug interactions. Drug Metabol Drug Interact 2004; 20(3): 143–58PubMedCrossRef
Metadata
Title
Herb-Drug Interactions
A Literature Review
Authors
Zeping Hu
Xiaoxia Yang
Paul Chi Lui Ho
Sui Yung Chan
Paul Wan Sia Heng
Eli Chan
Wei Duan
Hwee Ling Koh
Dr Shufeng Zhou
Publication date
01-06-2005
Publisher
Springer International Publishing
Published in
Drugs / Issue 9/2005
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI
https://doi.org/10.2165/00003495-200565090-00005

Other articles of this Issue 9/2005

Drugs 9/2005 Go to the issue

Adis Drug Profile

Infliximab in Ankylosing Spondylitis

Adis Drug Evaluation

Subcutaneous Recombinant Interferon-β-1a (Rebif®)

Adis Drug Profile

Infliximab

Leading Article

Short-Course Therapy for Community-Acquired Pneumonia in Paediatric Patients

Review Article

Traditional and Newer Therapeutic Options for Psoriatic Arthritis

Therapy in Practice

Use of Antipsychotics in the Management of Schizophrenia during Pregnancy